PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study To Find The Best Doses Of SU011248 (Sunitinib) And Capecitabine When These Drugs Are Administered Together
Phase 1
Completed
- Conditions
- Solid TumorsBreast CancerNeoplasms
- Interventions
- First Posted Date
- 2008-02-18
- Last Posted Date
- 2010-05-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 77
- Registration Number
- NCT00618124
- Locations
- 🇺🇸
Pfizer Investigational Site, Nashville, Tennessee, United States
Safety and Immunogenicity Study of MenC-TT Vaccine (NeisVac-C) in Toddlers Previously Immunized With PCV7 (Prevenar®)
Phase 3
Completed
- Conditions
- Invasive Pneumococcal Disease (IPD)Neisseria Meningitidis (Bacterial Meningitis)
- Interventions
- Biological: Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT)Biological: Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT) vaccine and 7-valent Pneumococcal CRM197-conjugate vaccine (PCV7)Biological: 7-valent Pneumococcal CRM197-conjugate vaccine (PCV7)
- First Posted Date
- 2008-02-18
- Last Posted Date
- 2015-05-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 330
- Registration Number
- NCT00617760
- Locations
- 🇩🇪
Hauptstrasse 240, Kehl, Baden-Württemberg, Germany
🇩🇪Werderstrasse 3, Bad Saulgau, Baden-Württemberg, Germany
🇩🇪Grossbottwarer Strasse 47, Oberestenfeld, Baden-Württemberg, Germany
A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients With Moderate to Severe Crohn's Disease
- First Posted Date
- 2008-02-14
- Last Posted Date
- 2013-01-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 139
- Registration Number
- NCT00615199
- Locations
- 🇬🇧
Pfizer Investigational Site, Salford, United Kingdom
A Study To Find The Best Doses Of SU011248 And Gemcitabine When Given Together To Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Solid Tumors
- Interventions
- Drug: SU011248; Gemcitabine
- First Posted Date
- 2008-02-14
- Last Posted Date
- 2010-04-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 44
- Registration Number
- NCT00615446
- Locations
- 🇺🇸
Pfizer Investigational Site, Boston, Massachusetts, United States
A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen
Phase 2
Completed
- Conditions
- Colorectal Neoplasms
- Interventions
- First Posted Date
- 2008-02-14
- Last Posted Date
- 2013-04-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 171
- Registration Number
- NCT00615056
- Locations
- 🇪🇸
Pfizer Investigational Site, Madrid, Spain
PH-797804 Versus Placebo For The Treatment Of Neuropathic Pain Associated With Post-Herpetic Neuralgia
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2011-05-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 80
- Registration Number
- NCT00614705
- Locations
- 🇬🇧
Pfizer Investigational Site, Solihull, United Kingdom
A 14-week, Multi-center Study of [S,S]-Reboxetine in Patients With Fibromyalgia.
Phase 3
Completed
- Conditions
- Fibromyalgia
- Interventions
- Drug: [S,S]-ReboxetineDrug: Placebo
- First Posted Date
- 2008-02-11
- Last Posted Date
- 2019-12-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1129
- Registration Number
- NCT00612170
- Locations
- 🇨🇦
Pfizer Investigational Site, Quebec, Canada
Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.
Phase 3
Completed
- Conditions
- Overactive Bladder
- Interventions
- First Posted Date
- 2008-02-08
- Last Posted Date
- 2011-02-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 2417
- Registration Number
- NCT00611026
- Locations
- 🇺🇦
Pfizer Investigational Site, Zaporizhzhia, Ukraine
Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer
Phase 2
Terminated
- Conditions
- Colorectal Neoplasms
- Interventions
- First Posted Date
- 2008-02-07
- Last Posted Date
- 2012-10-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 191
- Registration Number
- NCT00609622
- Locations
- 🇯🇵
Pfizer Investigational Site, Chuo-ku, Tokyo, Japan
Long-term OL Study of [S,S]-RBX in Patients With Fibromyalgia
Phase 3
Terminated
- Conditions
- Fibromyalgia
- Interventions
- Drug: [S,S]-reboxetine
- First Posted Date
- 2008-02-05
- Last Posted Date
- 2019-12-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 500
- Registration Number
- NCT00607256
- Locations
- 🇬🇧
Pfizer Investigational Site, Paisley, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath